Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study.

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  R. Shamburek,et al.  Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. , 2010, Clinical chemistry.

[3]  M. Davidson.  Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated? , 2009, Clinical cardiology.

[4]  M. Benn.  Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. , 2009, Atherosclerosis.

[5]  J. Kastelein,et al.  Triglycerides and Cardiovascular Risk , 2009, Current cardiology reviews.

[6]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[7]  A. Frasheri,et al.  Small, dense low‐density lipoproteins (LDL) are predictors of cardio‐ and cerebro‐vascular events in subjects with the metabolic syndrome , 2009, Clinical endocrinology.

[8]  Sridevi Devaraj,et al.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. , 2009, Clinical chemistry.

[9]  I. Holme,et al.  Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS) , 2009, Journal of internal medicine.

[10]  R. Prassl,et al.  Molecular structure of low density lipoprotein: current status and future challenges , 2009, European Biophysics Journal.

[11]  A. Scanu,et al.  HDL: bridging past and present with a look at the future , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S. Phinney,et al.  Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. , 2008, Progress in lipid research.

[13]  C. Furberg,et al.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. , 2008, Journal of the American College of Cardiology.

[14]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[15]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[16]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[17]  R. McPherson,et al.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. , 2006, The Canadian journal of cardiology.

[18]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[19]  H. E. Solberg,et al.  Detection of outliers in reference distributions: performance of Horn's algorithm. , 2005, Clinical chemistry.

[20]  R. Feinman,et al.  Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction , 2005, Nutrition & metabolism.

[21]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[22]  H. E. Solberg,et al.  The IFCC recommendation on estimation of reference intervals. The RefVal Program , 2004, Clinical chemistry and laboratory medicine.

[23]  E. Hawe,et al.  Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[24]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[25]  D. Topping,et al.  Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. , 2001, The Journal of nutrition.

[26]  P. Wilson,et al.  Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. , 1996, Clinical chemistry.

[27]  O. Impivaara,et al.  Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. , 1995, Clinical chemistry.

[28]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. , 1993 .

[29]  F. Dati,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. , 1991, Clinical chemistry.

[30]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[31]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[32]  B. Gersh,et al.  Thirty-five-year trends in cardiovascular risk factors in Finland , 2011 .

[33]  P. Wilson,et al.  Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. , 1996, Clinical chemistry.

[34]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. , 1994, Clinical chemistry.